Aeterna scraps Zoptrex after endometrial cancer miss

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) said it will end development of Zoptrex zoptarelin doxorubicin (formerly AEZS-108) after it missed the primary endpoint in the Phase III ZoptEC trial to treat endometrial cancer. The compound failed to improve overall survival compared to doxorubicin.

On Monday, Aeterna Zentaris lost C$2.72 (60%) to C$1.78 in Toronto and US$2 (60%) to US$1.35 on NASDAQ...